The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 524.46% and ...
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Here, we unpack the latest research on GLP ...
The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Chipotle is raising its U.S. prices to offset inflation and to compensate for a promise to increase portion sizes.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...